Hong Kong stock movement: China National Pharmaceutical Group rises 18.89%: Half-year net profit doubles, renamed SBP Group

Hong Kong Stock Movement

China Biologic Products Holdings Inc. rose 18.89%. Based on recent key news:

1. On August 19, China Biologic Products announced its performance for the first half of 2026, with revenue of 19.44 billion yuan, a year-on-year increase of 10.6%. Revenue from innovative drugs and external licensing grew by 44.3%, accounting for 45.2% of total revenue. This performance drove the stock price up. Source: China Biologic Products official website

2. On August 19, the company announced its name change to SBP Group, marking an upgrade in its international strategy. This move was seen by the market as a positive signal for the company's future growth, further boosting the stock price. Source: China Biologic Products official website

3. On August 20, market expectations for the company's intensive harvest period of innovative drugs increased, with nearly 30 innovative drugs expected to be approved for market from 2026 to 2030, significantly driving up the stock price. Source: China Biologic Products official website. The innovative drug development in the pharmaceutical industry is rapidly advancing, with a clear trend towards internationalization.

Stocks with High Trading Volume in the Industry

Shijiazhuang Yiling Pharmaceutical Co., Ltd. rose 15.08%. Based on recent key news:

1. On August 18, the new drug application for the combination of Anituzumab and Docetaxel developed by Shijiazhuang Yiling Pharmaceutical in collaboration with CanSino Biologics was accepted by the National Medical Products Administration of China and included in the priority review and approval process. This significantly boosted market confidence in Shijiazhuang Yiling Pharmaceutical, driving the stock price up.

2. On August 20, Shijiazhuang Yiling Pharmaceutical announced that its SYS6090 injection for the treatment of hepatocellular carcinoma has officially launched its Phase Ib/II clinical trial at the first center in China. The product has shown significant efficacy and good safety tolerance, further enhancing investor confidence in the company's R&D capabilities.

3. On August 19, Shijiazhuang Yiling Pharmaceutical announced the launch of the Phase Ib/II clinical trial for the safety, tolerance, and efficacy of SYS6090 injection in participants with hepatocellular carcinoma. This indicates the company's ongoing investment and progress in innovative drug R&D, boosting market sentiment. The innovative drug industry is experiencing a performance turning point, with significant commercialization growth.

Hengrui Medicine Co., Ltd. fell 6.82%. Based on recent key news:

1. On August 19, Hengrui Medicine announced plans to repurchase A-shares with its own funds, with a repurchase amount of no less than 1 billion yuan and no more than 2 billion yuan, at a price not exceeding 81.78 yuan per share. This move aims to improve the company's long-term employee incentive mechanism and motivate employees. Following the announcement, the stock price fell by about 6.82%.

2. On August 19, Hengrui Medicine released its semi-annual report for 2026, showing a year-on-year decline in operating revenue of 1.94% and a year-on-year increase in net profit of 0.34%. Although sales revenue from innovative drugs increased, the overall performance did not meet market expectations, putting pressure on the stock price.

3. On August 19, Hengrui Medicine announced that the implementation period for its share repurchase had expired, with a total of 16.591 million shares repurchased, accounting for 0.25% of the total share capital, at an average repurchase price of approximately 60.51 yuan per share, with a total repurchase amount of 1.004 billion yuan The repurchase news failed to boost market confidence, and stock prices continued to decline. Sales revenue from innovative drugs increased, but market expectations were not met.

Hansoh Pharmaceutical rose by 3.64%. Based on recent key news:

1. On August 18, Hansoh Pharmaceutical's ADC candidate drug HS-20093 achieved its primary endpoint in a Phase III trial for osteosarcoma. This progress significantly boosted market confidence in the company, driving the stock price up.

2. On August 18, Hansoh Pharmaceutical's GLP-1/GIP RA asset is closely tied to the popular obesity treatment market, prompting brokerages including CLSA to raise their target prices. This further enhanced bullish sentiment in the market.

3. Recently, the market environment has harshly punished information vacuums while disproportionately rewarding clinical progress and AI-driven profit expansion. Hansoh Pharmaceutical's clinical advancements and technological innovations have allowed it to benefit in this environment. The market has reacted positively to clinical progress and technological innovations.

Stocks ranked among the top in industry market capitalization

WuXi AppTec rose by 7.04%. Based on recent key news:

1. On August 17, the China Securities Hong Kong Stock Connect Innovative Drug Index rose by 1.34%, with WuXi AppTec, as a constituent stock, rising by 8.39%. Market attention on the pharmaceutical sector has intensified, with the global value realization and commercialization of innovative drug companies becoming the core focus of capital. Source: Zhitong Finance

2. On August 19, Guojin Securities pointed out that global biopharmaceutical investment and financing have warmed up, with WuXi AppTec's order scale increasing significantly by 31.7%. Domestic innovative drugs have reached a critical development node, driving the stock price up. Source: Zhitong Finance

3. On August 14, Goldman Sachs increased its holdings in WuXi AppTec by 44,100 shares, raising its ownership ratio to 5.1%. This move demonstrates institutional confidence in WuXi AppTec, further driving the stock price up. Source: Zhitong Finance. The attention on the pharmaceutical sector has intensified, with significant capital inflow